<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Radiation dermatitis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Radiation dermatitis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Radiation dermatitis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Julie Ryan Wolf, PhD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Angela M Hong, MBBS, MMed, PhD, FRANZCR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph Fowler, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David E Wazer, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H11060574">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation dermatitis is one of the most common side effects of radiotherapy for cancer, affecting over 90 percent of patients receiving radiotherapy [
         <a href="#rid1">
          1-6
         </a>
         ]. Cutaneous adverse effects of radiation therapy can be divided into early/acute reactions, occurring within 90 days of initiating treatment, and late effects, which often become apparent months to years after radiation treatment has been completed  (
         <a class="graphic graphic_table graphicRef89672" href="/z/d/graphic/89672.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         This topic will discuss the pathogenesis, clinical manifestations, and treatment of radiation dermatitis. The complications of breast and chest wall irradiation and radiation-induced fibrosis are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7055.html" rel="external">
          "Clinical manifestations, prevention, and treatment of radiation-induced fibrosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/754.html" rel="external">
          "Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse", section on 'Chest wall and breast complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1553109">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H44653694">
         <span class="h2">
          Acute effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Basal keratinocytes, stem cells in the hair follicles, and melanocytes are highly radiosensitive [
         <a href="#rid7">
          7-9
         </a>
         ]. During radiation therapy, the first fractionated dose of radiation causes immediate structural tissue damage, ionization of cellular water and generation of short-lived free radicals, irreversible double-stranded breaks in nuclear and mitochondrial deoxyribonucleic acid (DNA), and inflammation [
         <a href="#rid2">
          2,10-13
         </a>
         ]. The destruction of a large proportion of basal keratinocytes results in the disruption of the self-renewing property of the epidermis. Repeated exposures do not allow time for basal skin cells to replenish and maintain optimal renewal of the epidermis.
        </p>
        <p>
         Possible mechanisms leading to radiation-induced inflammation are summarized below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ionizing radiation incites signaling between the epidermis and dermis through resident skin cells. The hallmark of radiation-induced skin injury is the transendothelial migration of leukocytes and other immune cells from circulation to irradiated skin [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Keratinocytes, Langerhans cells, fibroblasts, and endothelial cells in the skin stimulate resident and circulating immune cells [
         <a href="#rid15">
          15,16
         </a>
         ]. Numerous cytokines and chemokines are produced in response to these activation signals, which act on the endothelial cells of local vessels, causing the upregulation of adhesion molecules (intercellular adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [VCAM-1], E-selectin) [
         <a href="#rid14">
          14,15,17
         </a>
         ]. Acute radiation skin toxicity has been correlated with increased formation of various cytokines and chemokines, in particular interleukin (IL) 1-alpha, IL-1-beta, tumor necrosis factor (TNF)-alpha, IL-6, IL-8, chemokine ligand 4 (CCL4), cysteine-X-cysteine motif chemokine ligand 10 (CXCL10), and chemokine ligand 2 (CCL2) [
         <a href="#rid14">
          14,18,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition, ionizing radiation induces degranulation of mast cells in the dermis [
         <a href="#rid16">
          16
         </a>
         ]. Research suggests that fibroblasts are a key cell type responsible for the late/delayed effect of radiation (ie, fibrosis) [
         <a href="#rid3">
          3,15,16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiation skin injury also involves imbalances in antioxidant status and redox control of wound healing [
         <a href="#rid12">
          12,14-16,20
         </a>
         ]. Specific enzymes that have been implicated in oxidative stress following radiation exposures include superoxide dismutases, glutathione peroxidases, thioredoxins, heme oxygenases, heat shock protein 27 (HSP27), and nitric oxide synthase [
         <a href="#rid12">
          12,20
         </a>
         ]. A T helper type 2 (Th2)-mediated immune response may also be responsible for nonresolution of inflammatory response and delayed wound healing following irradiation [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2395932544">
         <span class="h2">
          Late effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transforming growth factor (TGF)-beta levels are increased within hours of radiation exposure, and this is thought to be implicated in the late, radiation-induced, fibrotic changes [
         <a href="#rid21">
          21
         </a>
         ]. TGF-beta is a regulatory protein that controls cell proliferation and differentiation, wound healing, and synthesis of extracellular matrix components in normal tissue inflammatory response [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7055.html" rel="external">
          "Clinical manifestations, prevention, and treatment of radiation-induced fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3645260">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation dermatitis occurs in over 90 percent of patients receiving radiotherapy, especially in patients with breast cancer, head and neck cancer, skin cancer, lung cancer, or sarcoma [
         <a href="#rid1">
          1,7,23-25
         </a>
         ]. The reason for the higher incidence in these cancer patient populations is the higher radiation dose to the skin. In most cases, the skin reaction is mild or moderate, but approximately 20 to 45 percent of patients experience higher grade dermatitis with moist desquamation and ulceration  (
         <a class="graphic graphic_table graphicRef89702" href="/z/d/graphic/89702.html" rel="external">
          table 4B
         </a>
         ) [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         Signs and symptoms of radiation therapy adverse effects, including radiation dermatitis, may be underrecognized and underreported. In a United States study that included nearly 10,000 patients with breast cancer undergoing radiation therapy, 72 percent completed a patient-reported outcome questionnaire. Of these, 99 percent were matched to physician Common Terminology Criteria for Adverse Events (CTCAE) assessments performed within three days of the questionnaire completion [
         <a href="#rid28">
          28
         </a>
         ]. Among 5510 patients reporting at least one symptom (ie, pain, pruritus, edema, fatigue), underrecognition of at least one symptom occurred in 53 percent of cases. Factors independently associated with underrecognition included age younger than 50 years, being of Black or other than White ethnicity, receiving conventional fractionation, and male physician sex.
        </p>
        <p class="headingAnchor" id="H3645416">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors for radiation dermatitis include patient-related factors, radiation dosing and schedule, and use of concurrent chemotherapy  (
         <a class="graphic graphic_table graphicRef89701" href="/z/d/graphic/89701.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3440232152">
         <span class="h2">
          Patient related
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Body areas
         </strong>
         – Different areas of the body have different sensitivities to radiation  (
         <a class="graphic graphic_table graphicRef89701" href="/z/d/graphic/89701.html" rel="external">
          table 2
         </a>
         ). The most sensitive regions of the body are the anterior of the neck, extremities, chest, abdomen, and face [
         <a href="#rid3">
          3
         </a>
         ]. Hair follicles on the scalp as well as the breast tissue are also radiosensitive. In patients with breast cancer, larger breast size is associated with increased risk of grade 2 or higher radiation dermatitis [
         <a href="#rid29">
          29,30
         </a>
         ]. In addition, breast reconstructions and implants are associated with increased risk of severe radiation dermatitis due to the skin's inability to dissipate heat following reconstruction procedures. These reactions are usually confined to surfaces of transposed flaps or to mastectomy flaps [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comorbidities and lifestyle factors
         </strong>
         – Obesity, poor nutritional status, chronic sun exposure, and smoking appear to increase the risk of radiation dermatitis [
         <a href="#rid2">
          2-4,33,34
         </a>
         ]. In a French study of 200 patients with breast cancer, a body mass index (BMI) &gt;30 was associated with increased risk of grade ≥2 radiodermatitis [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Based upon limited evidence from case reports and small case series, patients with connective tissue diseases (and, in particular, those with scleroderma) were considered in the past to be at increased risk of severe, acute and chronic radiation dermatitis [
         <a href="#rid36">
          36
         </a>
         ]. In one study, skin thickening localized to the field of irradiation was reported in approximately 50 percent of patients with scleroderma [
         <a href="#rid37">
          37
         </a>
         ]. However, data from large case series and a few case-control studies do not show an increased frequency of acute or late complications in patients with connective tissue diseases undergoing radiation therapy [
         <a href="#rid38">
          38-40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">
          "Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Issues with specific therapies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5615.html" rel="external">
          "Malignancy and rheumatic disorders", section on 'Safety of radiation therapy for malignancy in patients with rheumatologic disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Staphylococcus aureus
          </em>
         </strong>
         <strong>
          colonization
         </strong>
         – It has been hypothesized that colonization with
         <em>
          S. aureus
         </em>
         may play a role in the development of severe radiation dermatitis [
         <a href="#rid41">
          41,42
         </a>
         ]. In a prospective study of 76 patients with breast or head and neck cancer undergoing radiation therapy, patients who developed grade 2 or higher dermatitis had a higher baseline prevalence of nasal
         <em>
          S. aureus
         </em>
         colonization compared with those with grade 1 dermatitis (35 versus 13 percent, respectively) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic susceptibility
         </strong>
         – Patients with inherited diseases associated with impaired DNA repair capacity, such as ataxia-telangiectasia, Bloom syndrome, Fanconi anemia, Gorlin syndrome, or xeroderma pigmentosum, are at risk of developing severe radiation dermatitis [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">
          "Ataxia-telangiectasia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">
          "Bloom syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">
          "Clinical manifestations and diagnosis of Fanconi anemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5340.html" rel="external">
          "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15466.html" rel="external">
          "Xeroderma pigmentosum"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, even in the absence of a known genetic disease, some individuals may have an increased susceptibility to radiation dermatitis. DNA sequencing studies have identified a number of single nucleotide polymorphisms (SNPs) associated with the development of radiation dermatitis [
         <a href="#rid43">
          43-46
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One study of 114 patients with locally advanced nasopharyngeal carcinoma found an association between the codon 399 Arg/Arg SNP in the X-ray repair cross-complementing gene 1 (
         <em>
          XRCC1
         </em>
         ) and risk of acute radiation dermatitis [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Another study of 446 female patients receiving radiation therapy after lumpectomy for breast cancer found that females with polymorphisms encoding reduced or absent activity in the glutathione S-transferases function had a greater than twofold increase in risk for acute radiation dermatitis [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In another study of 156 patients with breast cancer, SNPs that mapped to two genes,
         <em>
          ABCA1
         </em>
         and
         <em>
          IL12RB2
         </em>
         , were associated with a nearly threefold increased risk of radiation-induced dermatitis [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1546415160">
         <span class="h2">
          Radiation dosing and schedule
         </span>
         <span class="headingEndMark">
          —
         </span>
         The total dose, dose per fraction, and volume and surface area exposed to radiation influence the risk of radiation dermatitis. In addition, the use of bolus material to ensure full skin dose in certain clinical scenarios (eg, skin cancer, scar recurrence) enhances the development of radiation dermatitis.
        </p>
        <p>
         Among patients with early breast cancer undergoing adjuvant radiation therapy, evidence from observational studies and randomized trials indicates that hypofractionated radiotherapy (40 to 42.5 Gy given in three to four weeks) is associated with a lower risk of acute, toxic effects compared with conventionally fractionated radiotherapy (50 Gy in 25 fractions) [
         <a href="#rid47">
          47,48
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/739.html" rel="external">
          "Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a multicenter cohort study including 2309 patients with breast cancer treated with adjuvant radiotherapy, the frequency of moist desquamation, dry desquamation, and grade ≥2 dermatitis was significantly lower among patients treated with hypofractionated radiation therapy compared with those treated with conventional radiation therapy (6.6 versus 28.5 percent, 18.7 versus 58.8 percent, and 27.4 versus 62.6 percent, respectively) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar results were obtained in a randomized trial including 287 patients with breast cancer treated with hypofractionated or conventional radiation therapy [
         <a href="#rid47">
          47
         </a>
         ]. In this study, the rate of grade ≥2 dermatitis was 47 percent among patients treated with hypofractionated radiation therapy and 78 percent among those treated with conventional radiotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2016 Cochrane review, acute skin toxicity was reduced with hypofractionated radiation therapy (relative risk [RR] 0.32, 95% CI 0.22-0.45; two studies, 357 females) [
         <a href="#rid49">
          49
         </a>
         ]. Late subcutaneous fibrosis was similar with either hypofractionated or conventional schedule (RR 0.93, 95% CI 0.83-1.05; four studies, 5130 females).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3222616265">
         <span class="h2">
          Concurrent anticancer therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients receiving conventional chemotherapy agents (eg, anthracyclines, taxanes) or targeted anticancer therapy with epidermal growth factor receptor (EGFR) inhibitors plus radiation therapy are at increased risk of developing severe radiation dermatitis [
         <a href="#rid50">
          50,51
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">
          "Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of 15 randomized trials comparing chemoradiotherapy versus radiation therapy alone for the treatment of nasopharyngeal carcinoma, chemoradiotherapy was associated with a nearly doubled risk of severe (grade 3 or 4) radiation dermatitis (RR 1.80, 95% CI 1.13-2.88) [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a systematic review of 48 studies including 2152 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent radiotherapy and
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         , grade 3 or 4 radiation dermatitis developed in 32.5 percent of patients (95% CI 28.5-36.5 percent) [
         <a href="#rid52">
          52
         </a>
         ]. In a subsequent report of 51 patients treated with radiotherapy and cetuximab, grade 3 or 4 radiation dermatitis occurred in 43 percent of patients [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment with immune checkpoint inhibitors preceding or following radiation therapy
         <strong>
          does not
         </strong>
         seem to increase the risk of radiation dermatitis. In a meta-analysis of 23 clinical trials of immune checkpoint inhibitors plus radiation therapy for the treatment of various cancers, the overall rates of all-grade and severe dermatitis were 22 percent (95% CI 16-29) and 3 percent (95% CI 2-5), respectively, similar to the rates of skin toxicities reported for immune checkpoint inhibitor therapy alone [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3660169317">
         <span class="h1">
          PREVENTION
         </span>
        </p>
        <p class="headingAnchor" id="H298198797">
         <span class="h2">
          Modern radiation therapy techniques
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intensity-modulated radiation therapy
         </strong>
         – Intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT), advanced forms of radiation therapy that deliver radiation to the planned treatment volume while minimizing radiation to normal tissue outside the target, have been reported to reduce the occurrence of skin reactions. In a multicenter, randomized trial, 331 patients with breast cancer were treated postoperatively with adjuvant radiotherapy using either a standard wedge missing-tissue compensation technique or breast IMRT [
         <a href="#rid55">
          55
         </a>
         ]. Fewer patients experienced moist desquamation in the IMRT group than in the conventional radiotherapy group (31 versus 48 percent). In a multivariate analysis, breast IMRT decreased the risk of moist desquamation by nearly 60 percent (odds ratio [OR] 0.42, 95% CI 0.23-0.75). (See
         <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">
          "Radiation therapy techniques in cancer treatment", section on 'Intensity-modulated radiation therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypofractionated radiation therapy
         </strong>
         – Hypofractionated irradiation has become increasingly popular for breast radiation therapy [
         <a href="#rid56">
          56
         </a>
         ]. Hypofractionation delivers a higher fractionated radiation dose daily for an equivalent total dose over a shorter period of time (ie, fewer number of sessions). A prospective evaluation of hypofractionated versus standard fractionated therapy suggests that rates of dermatitis, pruritus, hyperpigmentation, and pain are decreased with hypofractionated therapy [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="local">
          'Radiation dosing and schedule'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Partial breast irradiation
         </strong>
         – Accelerated partial-breast irradiation (APBI) is an alternative to whole-breast irradiation in select low-risk patients with breast cancer after breast conservation surgery [
         <a href="#rid57">
          57
         </a>
         ]. APBI has been associated with a lower rate of acute toxicity without an increased risk of relapse compared with whole-breast radiotherapy [
         <a href="#rid58">
          58,59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/739.html" rel="external">
          "Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer", section on 'Accelerated partial-breast irradiation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1861629339">
         <span class="h2">
          General skin care
         </span>
         <span class="headingEndMark">
          —
         </span>
         The skin in the treatment area needs to be protected from irritation and friction during radiotherapy treatment and for two to four weeks after radiotherapy treatment has finished. General skin care measures for patients undergoing radiation therapy include [
         <a href="#rid7">
          7,24,33,60,61
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Keeping the irradiated area clean and dry.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Washing with lukewarm water and mild soap (liquid, synthetic, "soap-free" and fragrance-free body washes with a near-physiologic pH of 4 to 6 are preferable).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Using unscented, lanolin-free, water-based moisturizers two to three times per day, including a nontreatment day on the weekend.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding skin irritants, such as perfumes and alcohol-based lotions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wearing loose-fitting clothes to avoid friction injuries.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding corn starch or baby powder in skin folds.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding sun exposure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding wet shaving within the treatment area; an electric razor is a safe alternative.
        </p>
        <p>
        </p>
        <p>
         It is important to instruct patients to gently clean and dry the skin in the radiation field before each irradiation session:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Washing
         </strong>
         – The benefit of a washing routine during treatment for the prevention of severe radiation dermatitis has been evaluated in a few randomized trials involving patients with breast cancer and head and neck cancer and in one meta-analysis [
         <a href="#rid61">
          61-64
         </a>
         ]. Although washing practices do not seem to reduce the overall risk of developing radiation dermatitis, washing with soap and water or water alone is associated with a significant reduction in itching, erythema, and desquamation compared with no washing [
         <a href="#rid61">
          61,62
         </a>
         ]. Moreover, allowing patients to continue their normal hygiene routine may prevent unnecessary distress and social isolation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moisturizing
         </strong>
         – Although patients are typically advised to avoid applying topical moisturizers, gels, emulsions, or dressings shortly before radiation treatment, as they can cause a bolus effect (ie, increase in the radiation dose delivered to the epidermis) [
         <a href="#rid26">
          26
         </a>
         ], the application of moisturizers in small amounts is generally safe. A study that evaluated the dosimetric effect of topical agents commonly used for radiation dermatitis (ie, petrolatum-based ointment,
         <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">
          silver sulfadiazine
         </a>
         cream) by using optically stimulated luminescent dosimeters found that the surface radiation dose increased when a very thick layer (≥3 mm) of the topical agent was applied but did not increase if only a moderately thick layer (1 to 2 mm) was applied [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of deodorants
         </strong>
         – The use of deodorants (and, in particular, metallic deodorants) during radiation therapy has been debated due to concerns that the deposition of aluminum salts may influence the superficial radiation dose or cause a bolus effect [
         <a href="#rid66">
          66
         </a>
         ]. However, a randomized trial including 333 patients with breast cancer using aluminum-containing deodorants, non-aluminum-containing deodorants, or no deodorants during conventionally fractionated postoperative radiation therapy did not find any significant difference among the three groups in the incidence or severity of radiation dermatitis [
         <a href="#rid67">
          67
         </a>
         ]. Patients in the aluminum-containing deodorant group experienced significantly less sweating than the control group. The odds of their sweating being barely tolerable and frequently or always interfering with their daily activities was decreased by 85 percent (OR 0.15, 95% CI, 0.03-0.91).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1344747907">
         <span class="h2">
          Topical corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend topical corticosteroids for the prevention of severe radiation dermatitis and for the reduction of discomfort and itching [
         <a href="#rid60">
          60
         </a>
         ]. Low- to medium-potency topical corticosteroids (groups 4 and 6  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 3
         </a>
         )), such as
         <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">
          mometasone
         </a>
         furoate 0.1% or
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         butyrate 0.1% cream, are applied to the treatment field once or twice daily, starting on the day of the first radiotherapy session and continued through the entire treatment cycle.
        </p>
        <p>
         Evidence from several randomized trials and one meta-analysis indicates that the regular use of topical corticosteroids during radiation therapy treatment and for a few additional weeks after the completion of treatment may reduce the incidence of severe dermatitis (moist desquamation) [
         <a href="#rid62">
          62,68-72
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2017 meta-analysis including 10 randomized trials (919 participants with breast cancer) found that topical corticosteroids applied once or twice daily to the breast or chest wall from the first day of radiotherapy to up to three weeks after completion of radiotherapy reduced the risk of wet desquamation compared with placebo creams (OR 0.29, 95% CI 0.19-0.45) [
         <a href="#rid73">
          73
         </a>
         ]. All studies showed that the mean radiation dermatitis score assessed by the Radiation Therapy Oncology Group (RTOG) or Common Terminology Criteria for Adverse Events (CTCAE) version 3 was lower in the corticosteroid group than in the control group. Moreover, in six studies, patients' subjective reports of pruritus and burning were fewer in the topical corticosteroid group than in the control group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2018, randomized trial, 124 patients with breast cancer undergoing postmastectomy radiation therapy were treated with
         <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">
          mometasone
         </a>
         furoate 0.1% cream or an emollient cream twice daily, starting on the first day of radiation therapy and continuing until either the development of moist desquamation or two weeks after the completion of radiation therapy. Moist desquamation occurred in fewer women in the mometasone furoate group than in the emollient group (44 versus 67 percent, respectively) [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2021, phase 3, randomized trial that included 211 patients with head and neck cancer undergoing bilateral neck irradiation in combination with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         therapy, topical corticosteroids applied at least once daily and continued for two weeks post-treatment reduced the frequency of grade ≥3 radiation dermatitis compared with placebo (13.9 versus 25.5 percent, respectively) [
         <a href="#rid25">
          25
         </a>
         ]. The frequency of grade ≥2 radiation dermatitis was similar in the topical corticosteroid and placebo groups (73.3 percent [95% CI 64.6-81.9] and 80.4 percent [95% CI 72.7-88.1], respectively).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H527917993">
         <span class="h2">
          Other topical agents/dressings
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of other agents and dressings have also been evaluated in single randomized trials and in systematic reviews, including aloe vera,
         <a class="drug drug_general" data-topicid="10302" href="/z/d/drug information/10302.html" rel="external">
          trolamine
         </a>
         (triethanolamine),
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          sucralfate
         </a>
         ,
         <a class="drug drug_general" data-topicid="8643" href="/z/d/drug information/8643.html" rel="external">
          hyaluronic acid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">
          silver sulfadiazine
         </a>
         , petroleum-based ointments, ascorbic acid, allantoin, almond oil, olive oil, dexpanthenol, chamomile, calendula, barrier film, silver nylon dressings, and a silicone-based, film-forming gel dressing [
         <a href="#rid60">
          60,74-79
         </a>
         ]. However, there is limited or no evidence for efficacy of these topical agents in preventing or reducing the severity of radiation dermatitis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Silicone-based gel dressings
         </strong>
         – In a single-blind, randomized trial, 197 patients with head and neck cancer were treated with a silicone-based, film-forming gel dressing (StrataXRT) or a moisturizer (sorbolene) at the start of radiotherapy (twice a day until the skin reaction subsided, up to four weeks post-treatment) [
         <a href="#rid80">
          80
         </a>
         ]. The rates of grade 2 and grade 3 radiation dermatitis were lower in the active treatment group than in the control group (80 and 28 percent versus 91 and 45 percent, respectively). The risk of developing grade 2 or grade 3 radiation dermatitis was reduced by 40 and 50 percent, respectively, in the active treatment group compared with the control group, after adjusting for
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         treatment (hazard ratio [HR] 0.59, 95% CI 0.44-0.80, and HR 0.51, 95% CI 0.32-0.80, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another phase 3, intrapatient, randomized trial (n = 78) used a soft silicone dressing film (Mepitel), which was applied before the start of radiotherapy and for several weeks afterwards [
         <a href="#rid81">
          81
         </a>
         ]. The rate of moist desquamation was significantly reduced compared with control (0 percent with Mepitel film versus 26 percent with aqueous cream).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Silver nylon dressings
         </strong>
         – Silver nylon dressings, which have traditionally been used as burn wound dressings, have demonstrated some efficacy in reducing radiation-induced skin toxicity. In a small, randomized trial including 42 patients with anal or rectal cancer treated with radiation therapy, the use of silver nylon dressings was associated with a lower radiation dermatitis severity score compared with standard skin care [
         <a href="#rid82">
          82
         </a>
         ]. In contrast, in a randomized trial including 196 patients with breast cancer, silver nylon dressings did not reduce the incidence or severity of radiation dermatitis compared with standard skin care [
         <a href="#rid83">
          83
         </a>
         ]. However, patients in the silver nylon dressing group experienced less itching, pain, and burning compared with those in the standard care group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Silver
         </strong>
         <strong>
          sulfadiazine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">
          Silver sulfadiazine
         </a>
         is known to have anti-inflammatory and barrier-enhancing properties, which may protect radiation-damaged skin from other infectious agents [
         <a href="#rid84">
          84
         </a>
         ]. In a randomized trial including 102 patients with breast cancer, silver sulfadiazine 1% cream applied three times a day for three days a week for five weeks during radiotherapy and one week thereafter was compared with general skin care in the prevention of radiation dermatitis [
         <a href="#rid75">
          75
         </a>
         ]. Patients in the silver sulfadiazine group experienced a less severe dermatitis than patients in the control group (mean dermatitis score 5.49 versus 7.21, respectively).
        </p>
        <p>
        </p>
        <p>
         Evidence from a limited number of randomized trials does
         <strong>
          not
         </strong>
         support the use of aloe vera,
         <a class="drug drug_general" data-topicid="10302" href="/z/d/drug information/10302.html" rel="external">
          trolamine
         </a>
         (triethanolamine),
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          sucralfate
         </a>
         , or
         <a class="drug drug_general" data-topicid="8643" href="/z/d/drug information/8643.html" rel="external">
          hyaluronic acid
         </a>
         for the prevention of radiation dermatitis [
         <a href="#rid85">
          85-92
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aloe vera
         </strong>
         – In a randomized trial including 225 patients with breast cancer, more patients in the aloe vera gel group than in the aqueous cream group developed dry desquamation, dermatitis of grade 2 or higher, and greater pain [
         <a href="#rid87">
          87
         </a>
         ]. A subsequent systematic review did not find evidence for efficacy of aloe vera in preventing or minimizing radiation dermatitis in patients with cancer [
         <a href="#rid89">
          89
         </a>
         ]. A subsequent randomized trial found that the use of either an aloe cream or placebo cream during radiation therapy increased the incidence and severity of radiation dermatitis compared with a dry powder regimen (nonmetallic baby powder or cornstarch) [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trolamine
         </strong>
         – In a randomized trial, 166 patients with advanced squamous cell carcinoma of the head and neck were assigned to prophylactic
         <a class="drug drug_general" data-topicid="10302" href="/z/d/drug information/10302.html" rel="external">
          trolamine
         </a>
         , 175 patients were assigned to interventional trolamine, and 165 patients were assigned to institutional preference product [
         <a href="#rid85">
          85
         </a>
         ]. Grade ≥2 dermatitis was reported in 79, 77, and 79 percent of the three groups, respectively. In another trial including 254 patients with breast cancer, trolamine cream or calendula cream was applied after each session [
         <a href="#rid86">
          86
         </a>
         ]. The occurrence of acute radiation dermatitis of grade 2 or higher was significantly lower with the use of calendula cream than with trolamine cream (41 versus 63 percent, respectively). However, in a subsequent study including 420 patients with breast cancer, the incidence of grade ≥2 dermatitis was similar in patients using a calendula cream and in those using a water-based emollient cream [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sucralfate
         </strong>
         –
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          Sucralfate
         </a>
         cream for the prevention of radiation dermatitis was compared with aqueous cream or no treatment in a randomized trial including 357 patients undergoing radiotherapy to the head and neck, breast, or anorectal area. After five weeks, the severity of erythema, desquamation, itch, pain, and discomfort, as reported by patients, was similar in the three groups [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8643" href="/z/d/drug information/8643.html" rel="external">
          Hyaluronic acid
         </a>
         – In a meta-analysis of eight, randomized trials that included 500 patients with breast cancer, hyaluronic acid was associated with a lower-grade radiation dermatitis compared with phytosterol;
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          vitamin E
         </a>
         ; and omega-3, -6, and -9 [
         <a href="#rid93">
          93
         </a>
         ]. No difference was found between hyaluronic acid and emollients,
         <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">
          vitamin C
         </a>
         , and alginate.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H507950843">
         <span class="h2">
          Bacterial decolonization
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a small, randomized trial, 77 patients with breast or head and neck cancer undergoing radiation therapy were assigned to
         <em>
          S. aureus
         </em>
         decolonization (intranasal
         <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">
          mupirocin
         </a>
         2% ointment twice daily and
         <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">
          chlorhexidine
         </a>
         gluconate 4% body cleanser once daily for five consecutive days prior to radiation therapy and then for five days every two weeks throughout radiation therapy) or standard care (normal skin hygiene and emollients) [
         <a href="#rid94">
          94
         </a>
         ]. After completion of radiation therapy, the rates of colonization with
         <em>
          S. aureus
         </em>
         were significantly lower in the bacterial decolonization group compared with the standard of care group (5.4 versus 24.3 percent, respectively). None of the 39 patients treated with bacterial decolonization developed grade 2 or higher radiation dermatitis compared with 9 of 38 patients (24 percent) treated with standard of care. Of note, the use of topical corticosteroids was not included in standard of care during the conduct of the trial.
        </p>
        <p class="headingAnchor" id="H2260250762">
         <span class="h2">
          Systemic agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several oral agents have been evaluated in single small, randomized trials, including proteolytic enzymes (a combination of papain, trypsin, and chymotrypsin) [
         <a href="#rid95">
          95
         </a>
         ],
         <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">
          pentoxifylline
         </a>
         [
         <a href="#rid96">
          96
         </a>
         ], antioxidant supplements, zinc supplementation [
         <a href="#rid97">
          97
         </a>
         ],
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          sucralfate
         </a>
         [
         <a href="#rid98">
          98
         </a>
         ], and curcumin [
         <a href="#rid99">
          99
         </a>
         ]. However, there is little or no evidence for efficacy of any of these systemic treatments.
        </p>
        <p>
         Examples of studies that examined the role of systemic agents in the prevention of radiation dermatitis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a small, randomized study including 78 patients treated with postoperative radiation therapy for squamous cell carcinoma of the head and neck, oral
         <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">
          pentoxifylline
         </a>
         (400 mg three times daily) was not more effective than placebo in the prevention of acute radiation dermatitis [
         <a href="#rid96">
          96
         </a>
         ]. However, the authors noted a beneficial effect of pentoxifylline in reducing late skin changes, fibrosis, and skin necrosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a multicenter, randomized trial including 686 patients with breast cancer undergoing radiation therapy, curcumin 1.5 g per day taken throughout the prescribed course of radiotherapy and then for an additional week was not more effective than placebo in reducing the severity of radiation dermatitis [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11060596">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H705987294">
         <span class="h2">
          Skin findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute radiation dermatitis, defined as dermatitis occurring within 90 days of starting treatment, typically occurs gradually during a fractionated course of radiation therapy. The time of onset varies from days to weeks after starting radiotherapy. The skin changes  (
         <a class="graphic graphic_picture graphicRef89673 graphicRef140221 graphicRef140222" href="/z/d/graphic/89673.html" rel="external">
          picture 1A-C
         </a>
         ) depend upon the radiation dose and individual skin sensitivity and include  (
         <a class="graphic graphic_table graphicRef89672" href="/z/d/graphic/89672.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid101">
          101,102
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erythema
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Edema
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pigment changes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hair loss
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dry desquamation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moist desquamation
        </p>
        <p>
        </p>
        <p>
         During a fractionated course of 2 Gy per fraction of radiation therapy, erythema occurs at doses of 12 to 20 Gy, dry desquamation occurs at doses ≥20 Gy, and moist desquamation occurs at doses &gt;50 Gy or higher [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Patient-reported symptoms may include skin pain, pruritus, and fatigue [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2828770443">
         <span class="h2">
          Clinical course
         </span>
         <span class="headingEndMark">
          —
         </span>
         The acute dermatitis typically continues to progress up to 10 to 14 days after completion of radiation therapy  (
         <a class="graphic graphic_picture graphicRef89673" href="/z/d/graphic/89673.html" rel="external">
          picture 1A
         </a>
         ). Re-epithelialization usually begins within 10 days after radiation exposure in the absence of infection [
         <a href="#rid7">
          7
         </a>
         ]. Severe dermatitis (grade 4) with necrosis of the epidermis or underlying dermis is associated with prolonged inflammation and healing time, resulting in fibrosis and loss of adnexal elements.
        </p>
        <p class="headingAnchor" id="H1750546589">
         <span class="h2">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute radiation dermatitis is characterized by apoptotic keratinocytes, vacuolization of the basal layer, and epidermal edema. Depending upon the radiation dose, epidermal necrosis with blister formation and sloughing of the epidermis may be seen [
         <a href="#rid104">
          104
         </a>
         ]. These changes manifest clinically as "moist desquamation." Hyperkeratosis is seen with dry desquamation. Dermal changes include dermal and endothelial cell edema, vasodilation, erythrocyte extravasation, and fibrin thrombi in vessels. An inflammatory infiltrate is noted throughout the dermis.
        </p>
        <p class="headingAnchor" id="H1244063973">
         <span class="h2">
          Patients receiving EGFR inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients treated with epidermal growth factor receptor (EGFR) inhibitors and radiotherapy, the clinical presentation of radiation dermatitis may be different and more severe than that seen in patients treated with radiotherapy alone [
         <a href="#rid50">
          50,52,105
         </a>
         ]. The skin reaction develops earlier (in the first two weeks of starting radiation therapy) and is more often severe (grade 3 or 4), with marked xerosis, intense inflammation, and epidermal necrosis, resulting in superficial ulceration, spontaneous bleeding, and crusting  (
         <a class="graphic graphic_picture graphicRef122383" href="/z/d/graphic/122383.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid106">
          106-108
         </a>
         ]. Moreover, these patients may concurrently develop a papulopustular eruption typically induced by EGFR inhibitors [
         <a href="#rid108">
          108
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">
          "Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2641603377">
         <span class="h2">
          Grading
         </span>
         <span class="headingEndMark">
          —
         </span>
         The severity of radiation dermatitis can be assessed by several grading systems  (
         <a class="graphic graphic_table graphicRef89702" href="/z/d/graphic/89702.html" rel="external">
          table 4B
         </a>
         and
         <a class="graphic graphic_picture graphicRef89673" href="/z/d/graphic/89673.html" rel="external">
          picture 1A
         </a>
         ) [
         <a href="#rid2">
          2,7,24
         </a>
         ]. The most commonly used are the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), under injury, poisoning, and procedural complications  (
         <a class="graphic graphic_table graphicRef91257" href="/z/d/graphic/91257.html" rel="external">
          table 4A
         </a>
         ), and the Radiation Therapy Oncology Group (RTOG)/European Organisation for Research and Treatment of Cancer (EORTC) toxicity criteria [
         <a href="#rid56">
          56,109
         </a>
         ]. The RTOG/EORTC follows the same grading criteria as the NCI CTCAE, which are described below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NCI CTCAE grade 1
         </strong>
         – Faint erythema with dry desquamation. Mild dermatitis is characterized by mild, blanchable erythema or dry desquamation. The onset is typically within days to weeks of initiating therapy, and symptoms may fade within a month. Pruritus, hair loss, and decreased sweating are common, associated symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NCI CTCAE grade 2
         </strong>
         – Moderate dermatitis is characterized by moderate to brisk erythema and patchy, moist desquamation mostly confined to skin folds and creases. It may be associated with moderate edema. Moist desquamation is characterized by epidermal necrosis, fibrinous exudates, and often considerable pain [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NCI CTCAE grade 3
         </strong>
         – There is confluent, moist desquamation in locations other than skin folds. There may be bleeding when associated with trauma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NCI CTCAE grade 4
         </strong>
         – This is characterized by skin necrosis or ulceration of full-thickness dermis. Spontaneous bleeding from the involved site can occur. Skin graft may be indicated, and it can have life-threatening consequences.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NCI CTCAE grade 5
         </strong>
         – Death due to dermatitis alone is a very rare event.
        </p>
        <p>
        </p>
        <p>
         Although commonly used in clinical and research settings, these grading systems are highly subjective. Real-time laser Doppler flowmetry has been proposed as a quantitative method to detect changes in cutaneous microcirculation that relate to increased radiation-induced skin injury [
         <a href="#rid110">
          110
         </a>
         ]. A grading atlas has also been developed, based upon a selection of representative digital photographs of radiation dermatitis graded according to the CTCAE by an expert panel [
         <a href="#rid111">
          111
         </a>
         ]. Additionally, the NCI has established a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhealthcaredelivery.cancer.gov%2Fpro-ctcae%2F&amp;token=%2BXxGqWkgBSZ0BZH5STumyUclLmDksDbKHq5hH6iNVN0AzzUxQyIYu0lLdqQ7kgXdjB85BFh59u8Iz4SSL9irOQ%3D%3D&amp;TOPIC_ID=13668" target="_blank">
          Patient-Reported Outcomes version of the CTCAE
         </a>
         , which can aid in assessment of symptomatic adverse reactions from radiation therapy [
         <a href="#rid112">
          112-114
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H351453721">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation exposure reduces the skin's antimicrobial defenses, leading to an increased risk of bacterial infections in irradiated skin, most often from
         <em>
          S. aureus
         </em>
         [
         <a href="#rid62">
          62
         </a>
         ]. Bacterial cultures are indicated if there are clinical signs of infection.
        </p>
        <p>
         Radiation dermatitis has a negative impact on patients' quality of life, with larger effects in higher-grade dermatitis [
         <a href="#rid115">
          115
         </a>
         ]. The worsening of quality of life is especially marked for the physical domain (due to itching, burning, and irritation), followed by the emotional and functional domains.
        </p>
        <p class="headingAnchor" id="H2540924292">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of acute radiation dermatitis is clinical, based upon the finding of skin changes  (
         <a class="graphic graphic_picture graphicRef89673" href="/z/d/graphic/89673.html" rel="external">
          picture 1A
         </a>
         ) in a patient with a history of radiation therapy in the previous three months. The sharp demarcation of the skin changes and their limitation to the irradiated areas are important clues to the diagnosis. Subjective symptoms, including skin pain and pruritus, should also be assessed. Key elements of history are the duration of treatment and the cumulative dose of radiation.
        </p>
        <p>
         A skin biopsy is usually not necessary for the diagnosis of radiation dermatitis. However, histopathologic examination of a skin biopsy may be helpful if the diagnosis is uncertain. (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H984439113">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of radiation dermatitis includes other skin conditions that can develop during or after completing the treatment:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allergic contact dermatitis
         </strong>
         – Allergic contact dermatitis to cosmetics, skin care products, topical antibiotics, adhesive bandages, or simulation markings may mimic radiation dermatitis. Allergic contact dermatitis is usually associated with intense pruritus and responds to treatment with topical corticosteroids. (See
         <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">
          "Clinical features and diagnosis of allergic contact dermatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intertrigo
         </strong>
         – Intertrigo is a common, inflammatory condition of skin folds characterized by moist erythema, malodor, weeping, pruritus, and tenderness and is often associated with candidal or bacterial secondary infection  (
         <a class="graphic graphic_picture graphicRef78179" href="/z/d/graphic/78179.html" rel="external">
          picture 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/115366.html" rel="external">
          "Intertrigo"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiation port dermatophytosis
         </strong>
         – Dermatophyte infection rarely can occur at the site of irradiation [
         <a href="#rid116">
          116,117
         </a>
         ]. It presents as single or multiple, annular, erythematous plaques with a well-defined, scaling border  (
         <a class="graphic graphic_picture graphicRef75928" href="/z/d/graphic/75928.html" rel="external">
          picture 4
         </a>
         ). A potassium hydroxide (KOH) preparation can confirm the diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Herpes zoster
         </strong>
         – Herpes zoster (shingles) presents with grouped, erythematous papules, vesicles, and pustules typically located in a single dermatome, most often thoracic or lumbar  (
         <a class="graphic graphic_picture graphicRef126366" href="/z/d/graphic/126366.html" rel="external">
          picture 5
         </a>
         ). Pain, described as burning, throbbing, or stabbing, is the most common symptom. In cases with atypical presentation, polymerase chain reaction (PCR) testing can confirm the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Graft-versus-host disease
         </strong>
         – Acute graft-versus-host disease is a complication of hematopoietic cell transplantation. It presents with a maculopapular rash that initially involves the nape of the neck, ears, shoulders, and the palms of the hands. The rash may become generalized, with bullae and extensive skin sloughing  (
         <a class="graphic graphic_picture graphicRef66097" href="/z/d/graphic/66097.html" rel="external">
          picture 6
         </a>
         ). The histopathologic features are similar to those of radiation dermatitis and include vacuolization of the basal layer; apoptotic keratinocytes; satellite cell necrosis; and a superficial, perivascular, lymphocytic infiltrate  (
         <a class="graphic graphic_picture graphicRef61055" href="/z/d/graphic/61055.html" rel="external">
          picture 7
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/13760.html" rel="external">
          "Cutaneous manifestations of graft-versus-host disease (GVHD)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stevens-Johnson syndrome/toxic epidermal necrolysis
         </strong>
         – Severe radiation dermatitis shares clinical and histopathologic features with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), a rare, severe skin reaction typically induced by medication  (
         <a class="graphic graphic_picture graphicRef68458 graphicRef82150" href="/z/d/graphic/68458.html" rel="external">
          picture 8A-B
         </a>
         ). The differentiation of SJS/TEN from high-grade radiation dermatitis can be difficult in patients treated with both radiation therapy and conventional or targeted anticancer agents, although SJS/TEN usually also occurs in sites distant from radiation exposure  (
         <a class="graphic graphic_table graphicRef115844" href="/z/d/graphic/115844.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11060654">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of radiation dermatitis is guided by the severity of skin damage and involves general skin care measures, prevention and treatment of secondary skin infection, and the use of dressings [
         <a href="#rid60">
          60,84,118
         </a>
         ]. It is important to educate the patient and family/caregivers about the care of the patient's skin during treatment to reduce irritation and trauma, relieve discomfort, and promote healing.
        </p>
        <p class="headingAnchor" id="H1388050">
         <span class="h2">
          Patients with grade 1 dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with mild dermatitis (Radiation Therapy Oncology Group [RTOG] and National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 1 dermatitis  (
         <a class="graphic graphic_table graphicRef89702" href="/z/d/graphic/89702.html" rel="external">
          table 4B
         </a>
         )) have faint erythema and dry desquamation. In addition to general skin care measures, including cleansing and moisturizing with hydrophilic (oil-in-water) moisturizers, we suggest that patients continue (if already using for prevention) or initiate topical corticosteroids (groups 4 and 5  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 3
         </a>
         )) to control itch and irritation. Topical corticosteroids are applied once or twice daily and continued for two weeks postradiation therapy. (See
         <a class="local">
          'General skin care'
         </a>
         above and
         <a class="local">
          'Topical corticosteroids'
         </a>
         above.)
        </p>
        <p>
         Antihistamines are generally not effective in reducing pruritus related to radiation dermatitis.
        </p>
        <p>
         In patients with grade 1 radiation dermatitis, the use of special dressings does not seem to be effective in halting the progression of dermatitis. In a four-week, randomized trial, 278 patients with breast cancer and grade 1 radiation dermatitis were treated with a hydrocolloid dressing or placebo (a water-based spray) [
         <a href="#rid119">
          119
         </a>
         ]. At four weeks, the rates of local treatment failure, defined as skin deterioration or interruption of radiation therapy due to radiation dermatitis, were similar in the active treatment and placebo groups (49 versus 51 percent, respectively). The intensity of erythema and pain and quality-of-life scores were also similar in the two groups.
        </p>
        <p class="headingAnchor" id="H1029743162">
         <span class="h2">
          Patients with grade 2 to 3 dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with grade 2 and 3 dermatitis  (
         <a class="graphic graphic_table graphicRef89702" href="/z/d/graphic/89702.html" rel="external">
          table 4B
         </a>
         ) present with moist desquamation involving the skin folds (grade 2) or other skin areas (grade 3). Treatment involves measures aimed at preventing secondary skin infection and the use of dressings over the areas of skin sloughing [
         <a href="#rid26">
          26,60
         </a>
         ]. If infection occurs, standard therapy for bacterial infections should be initiated with topical and/or systemic antibiotics.
        </p>
        <p>
         For moist desquamation, we typically use soft, absorbent, silicone foam bandages (eg, Mepilex Lite, Biatain). This type of dressing is atraumatic to the wound and surrounding skin when removed. The bandage can be applied with or without topical agents (eg,
         <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">
          silver sulfadiazine
         </a>
         , amorphous hydrogels). The dressing should be changed daily or more frequently, depending upon the severity of weeping.
        </p>
        <p>
         The use of dressings in the management of moist desquamation is based upon the observation that a moist environment promotes the rate of re-epithelization and increases the speed of wound healing [
         <a href="#rid120">
          120
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15912.html" rel="external">
          "Basic principles of wound management", section on 'Wound dressings'
         </a>
         .)
        </p>
        <p>
         In clinical practice, a variety of wound dressings are used, including nonadherent, hydrogel, or hydrocolloid dressings (eg, StrataXRT, Mepitel, Mepilex) [
         <a href="#rid7">
          7
         </a>
         ]. However, there is little evidence to aid in the choice among the various types of dressings. A few randomized trials have compared different dressings or dressings versus other topical agents with inconclusive results [
         <a href="#rid121">
          121-123
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study, 100 patients with moist desquamation received dry, nonadherent dressing or hydrogel dressing [
         <a href="#rid121">
          121
         </a>
         ]. The time to healing was longer in the hydrogel group than in the dry dressing group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two small trials compared hydrogel or hydrocolloid dressing with
         <a class="drug drug_general" data-topicid="8749" href="/z/d/drug information/8749.html" rel="external">
          gentian violet
         </a>
         0.5% aqueous solution [
         <a href="#rid122">
          122,123
         </a>
         ]. In one study, patients in the hydrogel group were more likely to heal than patients in the gentian violet group [
         <a href="#rid122">
          122
         </a>
         ]. The median time to healing was 12 days for hydrogel dressing and more than 30 days for gentian violet. In another study, the healing time was similar for patients receiving hydrocolloid dressing and those receiving gentian violet (11.4 versus 11.7 days, respectively) [
         <a href="#rid123">
          123
         </a>
         ]. However, dressing comfort and acceptability were higher for hydrocolloid dressing than gentian violet. Grade 3 radiodermatitis with moist desquamation may require interruption of radiation therapy, depending upon the body location and the patient's discomfort.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H59961645">
         <span class="h2">
          Patients with grade 4 dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Grade 4 dermatitis  (
         <a class="graphic graphic_table graphicRef89702" href="/z/d/graphic/89702.html" rel="external">
          table 4B
         </a>
         ) is rare. Patients presenting with full-thickness skin necrosis and ulceration should be treated on a case-by-case basis. They may require discontinuation of radiation therapy and a multidisciplinary approach, involving a wound specialist, radiation oncologist, dermatologist, and nurse [
         <a href="#rid26">
          26
         </a>
         ]. Treatment may include surgical debridement, full-thickness skin graft, or myocutaneous or pedicle flaps. For infected or at-risk wounds, systemic or topical antibacterial agents should be considered. (See
         <a class="medical medical_review" href="/z/d/html/15912.html" rel="external">
          "Basic principles of wound management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1117180527">
         <span class="h2">
          Patients receiving concurrent EGFR inhibitor therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients receiving concurrent epidermal growth factor receptor (EGFR) inhibitor therapy who develop grade 1, 2, or 3 radiation dermatitis, interruption or dose reduction of the drug is not generally necessary [
         <a href="#rid26">
          26,108,124-126
         </a>
         ]. However, some experts suggest a dose reduction of
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         in patients with severe grade 3 reaction [
         <a href="#rid126">
          126
         </a>
         ]. Interruption of both radiation therapy and cetuximab is advised in patients with grade 4 reaction. Cetuximab should be interrupted until the skin reaction has resolved to at least grade 2 [
         <a href="#rid108">
          108,124
         </a>
         ].
        </p>
        <p>
         Patients treated with
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         may need additional treatment or prophylaxis for the papulopustular, acneiform eruption commonly associated with EGFR inhibitors. (See
         <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">
          "Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors", section on 'Management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">
          "Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors", section on 'Prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4039061845">
         <span class="h1">
          OTHER ACUTE REACTIONS TO RADIATION THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H325945226">
         <span class="h2">
          Radiation recall reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation recall is an acute, inflammatory reaction confined to an area of previous radiation exposure that is triggered by chemotherapeutic agents or other drugs [
         <a href="#rid127">
          127
         </a>
         ]. The reaction occurs in approximately 6 to 9 percent of patients receiving chemotherapy after radiation therapy; is drug specific for each individual; and can occur weeks, months, or years after radiation therapy [
         <a href="#rid127">
          127,128
         </a>
         ]. The diagnosis is based on the appearance within the previous radiation therapy field  (
         <a class="graphic graphic_picture graphicRef119159" href="/z/d/graphic/119159.html" rel="external">
          picture 9
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">
          "Cutaneous adverse effects of conventional chemotherapy agents", section on 'Radiation recall dermatitis and radiation enhancement'
         </a>
         .)
        </p>
        <p>
         Radiation recall occurs most frequently with conventional chemotherapy agents, in particular anthracyclines (
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ), taxanes (
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         ), and antimetabolites (
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         ) [
         <a href="#rid127">
          127
         </a>
         ]. However, it has also been reported in association with targeted anticancer agents, such as epidermal growth factor receptor (EGFR) inhibitors, B-Raf proto-oncogene (BRAF) inhibitors, and immune checkpoint inhibitors [
         <a href="#rid129">
          129-135
         </a>
         ].
        </p>
        <p>
         The clinical manifestations of radiation recall include mild rash, dry desquamation, pruritus, swelling, maculopapular eruptions, and ulceration [
         <a href="#rid127">
          127
         </a>
         ]. In approximately one-third of cases, recall reactions occur in other sites, such as the lungs, oral mucosa, and gastrointestinal system. After withdrawal of the drug, the reaction usually resolves within one to two weeks. The management is similar to that of acute radiation dermatitis.
        </p>
        <p class="headingAnchor" id="H4181681042">
         <span class="h2">
          Radiation burns
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation burns may occur rarely as a result from high exposure to radiation during repeated diagnostic medical imaging, interventional radiology procedures, or radiation therapy [
         <a href="#rid136">
          136
         </a>
         ]. The most distinctive feature of radiation burns compared with thermal burns is the difficulty in delineating radiation-injured tissue from uninjured tissue [
         <a href="#rid137">
          137,138
         </a>
         ]. This difficulty stems from the unpredictable progression of tissue injury, which can occur weeks to years after irradiation and often results in necrosis of skin grafts [
         <a href="#rid137">
          137,138
         </a>
         ]. Additional unique characteristics of radiation burns include a dose-dependent clinical pattern and opiate-resistant pain [
         <a href="#rid2">
          2,3,8,33,137,139
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3949796675">
         <span class="h2">
          Eosinophilic, polymorphic, and pruritic eruption
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eosinophilic, polymorphic, and pruritic eruption associated with radiotherapy (EPPER) is an uncommon reaction to radiation therapy that most commonly develops in patients with cervical cancer and breast cancer [
         <a href="#rid140">
          140-142
         </a>
         ]. EPPER presents with erythematous papules, pustules, excoriations, and occasionally wheals, vesicles, and bullae, accompanied by localized or generalized pruritus  (
         <a class="graphic graphic_picture graphicRef116749" href="/z/d/graphic/116749.html" rel="external">
          picture 10
         </a>
         ). The eruption is not confined to the irradiated area but may involve the adjacent areas and the upper and lower extremities. Biopsy shows a superficial and deep, perivascular, lymphohistiocytic infiltrate with eosinophils. Treatment includes topical and systemic corticosteroids and antihistamines. EPPER usually resolves in a few weeks after completing radiation therapy.
        </p>
        <p class="headingAnchor" id="H1355146408">
         <span class="h2">
          Fluoroscopy-induced subacute radiation dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subacute radiation dermatitis is an uncommon form of radiation dermatitis that typically presents weeks to a few months after the initial exposure to ionizing radiation during a diagnostic or interventional radiologic procedure [
         <a href="#rid143">
          143
         </a>
         ]. The clinical appearance is that of an erythematous patch or plaque over the irradiated area that may become indurated, hyperpigmented, and ulcerate [
         <a href="#rid144">
          144-146
         </a>
         ]. The diagnosis may be delayed given the delayed presentation and rarity.
        </p>
        <p>
         Histologically, fluoroscopy-induced subacute radiation dermatitis is indistinguishable from acute graft-versus-host disease or fixed drug reaction [
         <a href="#rid145">
          145
         </a>
         ]. Histologic findings include atypical keratinocytes, hypergranulosis, and compact hyperkeratosis. An interface dermatitis with keratinocyte necrosis is usually present. In addition, clefting along the dermal-epidermal junction, fibroblast proliferation, and telangiectatic vessels may be seen. The papillary dermis may show a variable, lymphocytic infiltrate with histiocytes around the papillary dermal plexus but no eosinophils, in contrast to fixed drug reactions.
        </p>
        <p class="headingAnchor" id="H999313658">
         <span class="h1">
          LATE-EFFECT CUTANEOUS REACTIONS OF RADIATION THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H3592715713">
         <span class="h2">
          Chronic radiation dermatitis
         </span>
        </p>
        <p class="headingAnchor" id="H1469014882">
         <span class="h3">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Late-effect or chronic radiation dermatitis typically presents months to years after radiation exposure [
         <a href="#rid24">
          24
         </a>
         ]. It is characterized by dermal fibrosis and poikilodermatous skin changes, including hyper- and hypopigmentation, atrophy, and telangiectasias  (
         <a class="graphic graphic_table graphicRef89672" href="/z/d/graphic/89672.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3,8,147
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2083638731">
         <span class="h3">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histologically, late-stage radiation dermatitis is characterized by eosinophilic, homogenized sclerosis of dermal collagen; scattered, large, atypical fibroblasts; absence of pilosebaceous units; and vascular changes. The deep vessels show fibrous thickening, sometimes with luminal obliteration and recanalization, whereas telangiectases are prominent in the upper dermis.
        </p>
        <p class="headingAnchor" id="H1651866447">
         <span class="h3">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several small, randomized trials suggest that prolonged treatment with
         <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">
          pentoxifylline
         </a>
         in combination with
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          vitamin E
         </a>
         for up to more than three years may be helpful for the treatment of subcutaneous radiation-induced fibrosis [
         <a href="#rid148">
          148-150
         </a>
         ]. However, the optimal dose and duration of therapy and the role of tocopherol have not been determined. It is also unclear whether this therapy should be continued indefinitely to maintain benefit.
        </p>
        <p>
         Physical therapy may include active and passive range of motion exercises, which may help to improve range of motion and reduce contractures. (See
         <a class="medical medical_review" href="/z/d/html/7055.html" rel="external">
          "Clinical manifestations, prevention, and treatment of radiation-induced fibrosis", section on 'Pentoxifylline plus tocopherol'
         </a>
         .)
        </p>
        <p>
         Hyperbaric oxygen has been evaluated as a treatment for radiation-induced fibrosis; however, there is currently insufficient evidence to show efficacy [
         <a href="#rid151">
          151
         </a>
         ].
        </p>
        <p>
         There are a few reports of successful treatment of radiation therapy-induced telangiectasias and hyperpigmentation with laser therapy [
         <a href="#rid152">
          152,153
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13638.html" rel="external">
          "Laser and light therapy for cutaneous vascular lesions"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">
          "Laser and light therapy for cutaneous hyperpigmentation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4204658993">
         <span class="h2">
          Postirradiation morphea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postirradiation morphea is a rare, late complication of radiotherapy occurring months to years after treatment and is characterized by the development of sclerotic plaques that resemble idiopathic morphea in the irradiated area. In some patients, sclerotic changes may also involve the adjacent, nonirradiated skin [
         <a href="#rid154">
          154,155
         </a>
         ]. Postirradiation morphea occurs in females undergoing radiation therapy for breast cancer in most cases, is associated with considerable morbidity and pain, and is cosmetically disfiguring  (
         <a class="graphic graphic_picture graphicRef67509" href="/z/d/graphic/67509.html" rel="external">
          picture 11
         </a>
         ) [
         <a href="#rid156">
          156
         </a>
         ]. In a retrospective study of 25 patients (23 females) with postirradiation morphea, 11 had a coexistent autoimmune disorder [
         <a href="#rid155">
          155
         </a>
         ].
        </p>
        <p>
         Treatment of postirradiation morphea is similar to that of idiopathic morphea and includes topical and intralesional corticosteroids, phototherapy, and systemic immunosuppressive agents in various combinations [
         <a href="#rid154">
          154
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16150.html" rel="external">
          "Morphea (localized scleroderma) in adults: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H828409552">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/126526.html" rel="external">
          "Society guideline links: Radiation dermatitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11060676">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology and risk factors
         </strong>
         – Radiation dermatitis is one of the most common side effects of radiotherapy for cancer, affecting approximately 90 percent of patients receiving radiotherapy, especially patients with breast cancer, head and neck cancer, lung cancer, or sarcoma. Risk factors for radiation dermatitis include body site, older age, female sex, and obesity  (
         <a class="graphic graphic_table graphicRef89701" href="/z/d/graphic/89701.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation and grading
         </strong>
         – Acute, radiation-induced skin changes  (
         <a class="graphic graphic_table graphicRef89672" href="/z/d/graphic/89672.html" rel="external">
          table 1
         </a>
         ) depend upon the radiation dose and include erythema, edema, pigment changes, epilation, and dry or moist desquamation  (
         <a class="graphic graphic_picture graphicRef89673" href="/z/d/graphic/89673.html" rel="external">
          picture 1A
         </a>
         ). The severity of radiation dermatitis is commonly assessed by using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) or the Radiation Therapy Oncology Group (RTOG) toxicity scoring system and ranges from mild (grade 1) to severe (grade 3 and 4)  (
         <a class="graphic graphic_table graphicRef91257 graphicRef89702" href="/z/d/graphic/91257.html" rel="external">
          table 4A-B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of acute radiation dermatitis is clinical, based upon the finding of erythema, dry desquamation, or moist desquamation in a patient with a recent history of radiation therapy. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Radiation therapy techniques
         </strong>
         – Modern radiation therapy techniques, such as intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT), which deliver radiation to the planned treatment volume while minimizing radiation to normal tissue outside the target, may reduce the occurrence of radiation dermatitis. (See
         <a class="local">
          'Modern radiation therapy techniques'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical corticosteroids
         </strong>
         – For patients undergoing radiation therapy, we recommend prophylactic topical corticosteroids in addition to general skin care measures for the prevention of severe radiation dermatitis (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Low- to medium-potency topical corticosteroids (groups 4 to 6  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 3
         </a>
         )) are applied to the treatment field once or twice daily after each radiotherapy session. Agents of unproven efficacy include aloe vera,
         <a class="drug drug_general" data-topicid="10302" href="/z/d/drug information/10302.html" rel="external">
          trolamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          sucralfate
         </a>
         ,
         <a class="drug drug_general" data-topicid="8643" href="/z/d/drug information/8643.html" rel="external">
          hyaluronic acid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">
          silver sulfadiazine
         </a>
         , and silver nylon dressings. (See
         <a class="local">
          'Topical corticosteroids'
         </a>
         above and
         <a class="local">
          'General skin care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of radiation dermatitis is guided by the severity of skin damage  (
         <a class="graphic graphic_table graphicRef89702" href="/z/d/graphic/89702.html" rel="external">
          table 4B
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with grade 1 radiation dermatitis usually do not require any specific treatment in addition to general skin care measures. (See
         <a class="local">
          'Patients with grade 1 dermatitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with grade 2 to 3 radiation dermatitis and moist desquamation, we typically use soft, absorbent, silicone foam bandages. Bacterial superinfection is treated with topical and/or systemic antibiotics. (See
         <a class="local">
          'Patients with grade 2 to 3 dermatitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with grade 4 radiation dermatitis who present with full-thickness skin necrosis may require surgical debridement and full-thickness skin graft or myocutaneous or pedicle flaps. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1758870533">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate would like to acknowledge Marilyn Ling, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hickok JT, Morrow GR, Roscoe JA, et al. Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer. J Pain Symptom Manage 2005; 30:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol 2006; 54:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown KR, Rzucidlo E. Acute and chronic radiation injury. J Vasc Surg 2011; 53:15S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bray FN, Simmons BJ, Wolfson AH, Nouri K. Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy. Dermatol Ther (Heidelb) 2016; 6:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh M, Alavi A, Wong R, Akita S. Radiodermatitis: A Review of Our Current Understanding. Am J Clin Dermatol 2016; 17:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leventhal J, Young MR. Radiation Dermatitis: Recognition, Prevention, and Management. Oncology (Williston Park) 2017; 31:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McQuestion M. Evidence-based skin care management in radiation therapy: clinical update. Semin Oncol Nurs 2011; 27:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendelsohn FA, Divino CM, Reis ED, Kerstein MD. Wound care after radiation therapy. Adv Skin Wound Care 2002; 15:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shakhov AN, Singh VK, Bone F, et al. Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2). PLoS One 2012; 7:e33044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López E, Guerrero R, Núñez MI, et al. Early and late skin reactions to radiotherapy for breast cancer and their correlation with radiation-induced DNA damage in lymphocytes. Breast Cancer Res 2005; 7:R690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McBride WH, Chiang CS, Olson JL, et al. A sense of danger from radiation. Radiat Res 2004; 162:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams JP, McBride WH. After the bomb drops: a new look at radiation-induced multiple organ dysfunction syndrome (MODS). Int J Radiat Biol 2011; 87:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kišonas J, Venius J, Grybauskas M, et al. Acute Radiation Dermatitis Evaluation with Reflectance Confocal Microscopy: A Prospective Study. Diagnostics (Basel) 2021; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holler V, Buard V, Gaugler MH, et al. Pravastatin limits radiation-induced vascular dysfunction in the skin. J Invest Dermatol 2009; 129:1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller K, Meineke V. Radiation-induced alterations in cytokine production by skin cells. Exp Hematol 2007; 35:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller K, Meineke V. Radiation-induced mast cell mediators differentially modulate chemokine release from dermal fibroblasts. J Dermatol Sci 2011; 61:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan H, Goetz DJ, Gaber MW, et al. Radiation-induced up-regulation of adhesion molecules in brain microvasculature and their modulation by dexamethasone. Radiat Res 2005; 163:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okunieff P, Xu J, Hu D, et al. Curcumin protects against radiation-induced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines. Int J Radiat Oncol Biol Phys 2006; 65:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiao Z, Su Y, Yang S, et al. Protective effect of esculentoside A on radiation-induced dermatitis and fibrosis. Int J Radiat Oncol Biol Phys 2006; 65:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benderitter M, Isoir M, Buard V, et al. Collapse of skin antioxidant status during the subacute period of cutaneous radiation syndrome: a case report. Radiat Res 2007; 167:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 2000; 47:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pohlers D, Brenmoehl J, Löffler I, et al. TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta 2009; 1792:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yee C, Wang K, Asthana R, et al. Radiation-induced Skin Toxicity in Breast Cancer Patients: A Systematic Review of Randomized Trials. Clin Breast Cancer 2018; 18:e825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvo N, Barnes E, van Draanen J, et al. Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Curr Oncol 2010; 17:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yokota T, Zenda S, Ota I, et al. Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation. Int J Radiat Oncol Biol Phys 2021; 111:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santa Cruz O, Tsoutsou P, Castella C, et al. Locoregional Control and Toxicity in Head and Neck Carcinoma Patients following Helical Tomotherapy-Delivered Intensity-Modulated Radiation Therapy Compared with 3D-CRT Data. Oncology 2018; 95:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagsi R, Griffith KA, Vicini F, et al. Identifying Patients Whose Symptoms Are Underrecognized During Treatment With Breast Radiotherapy. JAMA Oncol 2022; 8:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dzul S, Ninia J, Jang H, et al. Predictors of Acute Radiation Dermatitis and Esophagitis in African American Patients Receiving Whole-Breast Radiation Therapy. Pract Radiat Oncol 2022; 12:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Córdoba EE, Lacunza E, Güerci AM. Clinical factors affecting the determination of radiotherapy-induced skin toxicity in breast cancer. Radiat Oncol J 2021; 39:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delfino S, Brunetti B, Toto V, Persichetti P. Burn after breast reconstruction. Burns 2008; 34:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandeweyer E, Deraemaecker R. Radiation therapy after immediate breast reconstruction with implants. Plast Reconstr Surg 2000; 106:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan JL. Ionizing radiation: the good, the bad, and the ugly. J Invest Dermatol 2012; 132:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer F, Fortin A, Wang CS, et al. Predictors of severe acute and late toxicities in patients with localized head-and-neck cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2012; 82:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas A, Keller A, Menoux I, et al. [Prognostic factors of acute radiodermatitis in breast cancer after adjuvant radiotherapy treated with RT3D or IMRT]. Cancer Radiother 2022; 26:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin A, Abu-Isa E, Griffith KA, Ben-Josef E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer 2008; 113:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah DJ, Hirpara R, Poelman CL, et al. Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer. Arthritis Care Res (Hoboken) 2018; 70:1517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giaj-Levra N, Sciascia S, Fiorentino A, et al. Radiotherapy in patients with connective tissue diseases. Lancet Oncol 2016; 17:e109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold DG, Miller RC, Pinn ME, et al. Chronic toxicity risk after radiotherapy for patients with systemic sclerosis (systemic scleroderma) or systemic lupus erythematosus: association with connective tissue disorder severity. Radiother Oncol 2008; 87:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold DG, Miller RC, Petersen IA, Osborn TG. Radiotherapy for malignancy in patients with scleroderma: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys 2007; 67:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill A, Hanson M, Bogle MA, Duvic M. Severe radiation dermatitis is related to Staphylococcus aureus. Am J Clin Oncol 2004; 27:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kost Y, Rzepecki AK, Deutsch A, et al. Association of Staphylococcus aureus Colonization With Severity of Acute Radiation Dermatitis in Patients With Breast or Head and Neck Cancer. JAMA Oncol 2023; 9:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambrosone CB, Tian C, Ahn J, et al. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res 2006; 8:R40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang A, Glick SA. Genetic susceptibility to cutaneous radiation injury. Arch Dermatol Res 2017; 309:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen H, Wu M, Li G, et al. Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma: A cohort study. Medicine (Baltimore) 2017; 96:e8202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isomura M, Oya N, Tachiiri S, et al. IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res 2008; 14:6683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaitelman SF, Schlembach PJ, Arzu I, et al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol 2015; 1:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagsi R, Griffith KA, Boike TP, et al. Differences in the Acute Toxic Effects of Breast Radiotherapy by Fractionation Schedule: Comparative Analysis of Physician-Assessed and Patient-Reported Outcomes in a Large Multicenter Cohort. JAMA Oncol 2015; 1:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hickey BE, James ML, Lehman M, et al. Fraction size in radiation therapy for breast conservation in early breast cancer. Cochrane Database Syst Rev 2016; 7:CD003860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tejwani A, Wu S, Jia Y, et al. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009; 115:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He Y, Guo T, Guan H, et al. Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: a meta-analysis. Cancer Manag Res 2018; 10:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonomo P, Loi M, Desideri I, et al. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review. Crit Rev Oncol Hematol 2017; 120:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonomo P, Desideri I, Loi M, et al. Management of severe bio-radiation dermatitis induced by radiotherapy and cetuximab in patients with head and neck cancer: emphasizing the role of calcium alginate dressings. Support Care Cancer 2019; 27:2957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan BY, Wasilewski G, Lacouture ME, Barker CA. Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis. J Am Acad Dermatol 2021; 84:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008; 26:2085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kole AJ, Kole L, Moran MS. Acute radiation dermatitis in breast cancer patients: challenges and solutions. Breast Cancer (Dove Med Press) 2017; 9:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forster T, Köhler CVK, Debus J, Hörner-Rieber J. Accelerated Partial Breast Irradiation: A New Standard of Care? Breast Care (Basel) 2020; 15:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017; 390:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet 2019; 394:2165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong RK, Bensadoun RJ, Boers-Doets CB, et al. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer 2013; 21:2933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Q, Wang Y, Yang S, et al. What is the appropriate skin cleaning method for nasopharyngeal cancer radiotherapy patients? A randomized controlled trial. Support Care Cancer 2022; 30:3875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan RJ, Webster J, Chung B, et al. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer 2014; 14:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell IR, Illingworth MH. Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial. Clin Oncol (R Coll Radiol) 1992; 4:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy I, Fortin A, Larochelle M. The impact of skin washing with water and soap during breast irradiation: a randomized study. Radiother Oncol 2001; 58:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumann BC, Verginadis II, Zeng C, et al. Assessing the Validity of Clinician Advice That Patients Avoid Use of Topical Agents Before Daily Radiotherapy Treatments. JAMA Oncol 2018; 4:1742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumann BC, Zeng C, Freedman GM, et al. Avoiding antiperspirants during breast radiation therapy: Myth or sound advice? Radiother Oncol 2017; 124:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis L, Carson S, Bydder S, et al. Evaluating the effects of aluminum-containing and non-aluminum containing deodorants on axillary skin toxicity during radiation therapy for breast cancer: a 3-armed randomized controlled trial. Int J Radiat Oncol Biol Phys 2014; 90:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meghrajani CF, Co HS, Arcillas JG, et al. A randomized, double-blind trial on the use of 1% hydrocortisone cream for the prevention of acute radiation dermatitis. Expert Rev Clin Pharmacol 2016; 9:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulff E, Maroti M, Serup J, et al. Prophylactic treatment with a potent corticosteroid cream ameliorates radiodermatitis, independent of radiation schedule: A randomized double blinded study. Radiother Oncol 2017; 122:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RC, Schwartz DJ, Sloan JA, et al. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys 2011; 79:1460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindley A, Zain Z, Wood L, et al. Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy: results of a randomized trial. Int J Radiat Oncol Biol Phys 2014; 90:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho AY, Olm-Shipman M, Zhang Z, et al. A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation. Int J Radiat Oncol Biol Phys 2018; 101:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haruna F, Lipsett A, Marignol L. Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis. Anticancer Res 2017; 37:5343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira EB, Vasques CI, Gadia R, et al. Topical interventions to prevent acute radiation dermatitis in head and neck cancer patients: a systematic review. Support Care Cancer 2017; 25:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemati S, Asnaashari O, Sarvizadeh M, et al. Topical silver sulfadiazine for the prevention of acute dermatitis during irradiation for breast cancer. Support Care Cancer 2012; 20:1613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan RJ, Mann J, Tripcony L, et al. Natural oil-based emulsion containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer: a phase 3, double-blind, randomized, controlled trial. Int J Radiat Oncol Biol Phys 2014; 90:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam AC, Yu E, Vanwynsberghe D, et al. Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Post-lumpectomy Patients with Breast Cancer Receiving Adjuvant Radiation Therapy. Cureus 2019; 11:e4807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahimi A, Mohamad O, Albuquerque K, et al. Novel hyaluronan formulation for preventing acute skin reactions in breast during radiotherapy: a randomized clinical trial. Support Care Cancer 2020; 28:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira EB, Ciol MA, de Meneses AG, et al. Chamomile Gel versus Urea Cream to Prevent Acute Radiation Dermatitis in Head and Neck Cancer Patients: Results from a Preliminary Clinical Trial. Integr Cancer Ther 2020; 19:1534735420962174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan RJ, Blades R, Jones L, et al. A single-blind, randomised controlled trial of StrataXRT® - A silicone-based film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer. Radiother Oncol 2019; 139:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herst PM, Bennett NC, Sutherland AE, et al. Prophylactic use of Mepitel Film prevents radiation-induced moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients. Radiother Oncol 2014; 110:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niazi TM, Vuong T, Azoulay L, et al. Silver clear nylon dressing is effective in preventing radiation-induced dermatitis in patients with lower gastrointestinal cancer: results from a phase III study. Int J Radiat Oncol Biol Phys 2012; 84:e305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aquino-Parsons C, Lomas S, Smith K, et al. Phase III Study of Silver Leaf Nylon Dressing vs Standard Care for Reduction of Inframammary Moist Desquamation in Patients Undergoing Adjuvant Whole Breast Radiation Therapy. J Med Imaging Radiat Sci 2010; 41:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenthal A, Israilevich R, Moy R. Management of acute radiation dermatitis: A review of the literature and proposal for treatment algorithm. J Am Acad Dermatol 2019; 81:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott EA, Wright JR, Swann RS, et al. Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. J Clin Oncol 2006; 24:2092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pommier P, Gomez F, Sunyach MP, et al. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. J Clin Oncol 2004; 22:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heggie S, Bryant GP, Tripcony L, et al. A Phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue. Cancer Nurs 2002; 25:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharp L, Finnilä K, Johansson H, et al. No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions--results from a randomised blinded trial. Eur J Oncol Nurs 2013; 17:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson J, Smith JE, McIntyre M, et al. Aloe vera for preventing radiation-induced skin reactions: a systematic literature review. Clin Oncol (R Coll Radiol) 2005; 17:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells M, Macmillan M, Raab G, et al. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol 2004; 73:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoopfer D, Holloway C, Gabos Z, et al. Three-Arm Randomized Phase III Trial: Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy. Clin Breast Cancer 2015; 15:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menêses AG, Reis PEDD, Guerra ENS, et al. Use of trolamine to prevent and treat acute radiation dermatitis: a systematic review and meta-analysis. Rev Lat Am Enfermagem 2018; 26:e2929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CJ, Fang HF, Wang CY, et al. Effect of hyaluronic acid on radiodermatitis in patients with breast cancer: a meta-analysis of randomized controlled trials. Support Care Cancer 2022; 30:3965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kost Y, Deutsch A, Mieczkowska K, et al. Bacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial. JAMA Oncol 2023; 9:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaul R, Mishra BK, Sutradar P, et al. The role of Wobe-Mugos in reducing acute sequele of radiation in head and neck cancers--a clinical phase-III randomized trial. Indian J Cancer 1999; 36:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aygenc E, Celikkanat S, Kaymakci M, et al. Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study. Otolaryngol Head Neck Surg 2004; 130:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. Int J Radiat Oncol Biol Phys 2006; 65:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lievens Y, Haustermans K, Van den Weyngaert D, et al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother Oncol 1998; 47:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan JL, Heckler CE, Ling M, et al. Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients. Radiat Res 2013; 180:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan Wolf J, Heckler CE, Guido JJ, et al. Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients. Support Care Cancer 2018; 26:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen JM, Gau T, Schultze J, et al. Treatment of acute radiodermatitis with an oil-in-water emulsion following radiation therapy for breast cancer: a controlled, randomized trial. Strahlenther Onkol 2011; 187:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmuth M, Sztankay A, Weinlich G, et al. Permeability barrier function of skin exposed to ionizing radiation. Arch Dermatol 2001; 137:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milton L, Behroozian T, Li N, et al. Symptom Burden Associated With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy. Clin Breast Cancer 2022; 22:e387.
          </a>
         </li>
         <li class="breakAll">
          Junkins-Hopkin JM. Disorders associated with physical agents: Heat, cold, radiation, and trauma. In: Lever's Histopathology of the Skin, 10th ed, Elder DE, Elenitsas R, Johnson B, et al (Eds), Wolters Kluwer-Lippincott Williams &amp; Wilkins, 2009.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 19:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Budach W, Bölke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007; 357:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koutcher LD, Wolden S, Lee N. Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab. Am J Clin Oncol 2009; 32:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernier J, Russi EG, Homey B, et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol 2011; 22:2191.
          </a>
         </li>
         <li class="breakAll">
          Fowble B, Park C, Yuen F. Breast cancer. In: Skin Care in Radiation Oncology: A Practical Guide, Fowble B, Yom SS, Yuen F, Arron S (Eds), Springer, 2016. p.93.
         </li>
         <li>
          <a class="nounderline abstract_t">
           González Sanchis A, Brualla González L, Sánchez Carazo JL, et al. Evaluation of acute skin toxicity in breast radiotherapy with a new quantitative approach. Radiother Oncol 2017; 122:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zenda S, Ota Y, Tachibana H, et al. A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients. J Radiat Res 2016; 57:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book 2016; 35:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kluetz PG, Slagle A, Papadopoulos EJ, et al. Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms. Clin Cancer Res 2016; 22:1553.
          </a>
         </li>
         <li class="breakAll">
          National Cancer Institute. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). https://healthcaredelivery.cancer.gov/pro-ctcae/ (Accessed on October 11, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rzepecki A, Birnbaum M, Ohri N, et al. Characterizing the effects of radiation dermatitis on quality of life: A prospective survey-based study. J Am Acad Dermatol 2022; 86:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casamiquela KM, Cohen PR. Radiation port dermatophytosis: tinea corporis occurring at the site of irradiated skin. Dermatol Online J 2012; 18:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen T, Dupuy J, Maor M, Altman A. Radiation port dermatophytosis. J Am Acad Dermatol 1988; 19:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behroozian T, Bonomo P, Patel P, et al. Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations. Lancet Oncol 2023; 24:e172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bazire L, Fromantin I, Diallo A, et al. Hydrosorb® versus control (water based spray) in the management of radio-induced skin toxicity: Results of multicentre controlled randomized trial. Radiother Oncol 2015; 117:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WINTER GD. Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature 1962; 193:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macmillan MS, Wells M, MacBride S, et al. Randomized comparison of dry dressings versus hydrogel in management of radiation-induced moist desquamation. Int J Radiat Oncol Biol Phys 2007; 68:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gollins S, Gaffney C, Slade S, Swindell R. RCT on gentian violet versus a hydrogel dressing for radiotherapy-induced moist skin desquamation. J Wound Care 2008; 17:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mak SS, Molassiotis A, Wan WM, et al. The effects of hydrocolloid dressing and gentian violet on radiation-induced moist desquamation wound healing. Cancer Nurs 2000; 23:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villavicencio M, Granados-García M, Vilajosana E, Domínguez-Cherit J. Management of radiodermatitis associated with cetuximab in squamous cell carcinomas of the head and neck. Int J Dermatol 2017; 56:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu G, Lin JC, Kim SB, et al. Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma. BMC Cancer 2016; 16:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto C, Barone CA, Girolomoni G, et al. Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy: Update of the Italian Expert Recommendations. Am J Clin Oncol 2016; 39:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burris HA 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist 2010; 15:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kodym E, Kalinska R, Ehringfeld C, et al. Frequency of radiation recall dermatitis in adult cancer patients. Onkologie 2005; 28:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boussemart L, Boivin C, Claveau J, et al. Vemurafenib and radiosensitization. JAMA Dermatol 2013; 149:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy A, Hollebecque A, Bourgier C, et al. Targeted therapy-induced radiation recall. Eur J Cancer 2013; 49:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forschner A, Zips D, Schraml C, et al. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 2014; 24:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anker CJ, Grossmann KF, Atkins MB, et al. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys 2016; 95:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korman AM, Tyler KH, Kaffenberger BH. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma. Int J Dermatol 2017; 56:e75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yigit E, Guven DC, Aksoy S, Yazici G. Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review. Cureus 2021; 13:e15548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Billena C, Padia S, O'Brien B, et al. Radiation recall dermatitis after treatment of stage IV breast cancer with nivolumab: a case report. Immunotherapy 2020; 12:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waghmare CM. Radiation burn--from mechanism to management. Burns 2013; 39:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bey E, Prat M, Duhamel P, et al. Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived stem cell administrations. Wound Repair Regen 2010; 18:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lataillade JJ, Doucet C, Bey E, et al. New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy. Regen Med 2007; 2:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolbarst AB, Wiley AL Jr, Nemhauser JB, et al. Medical response to a major radiologic emergency: a primer for medical and public health practitioners. Radiology 2010; 254:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rueda RA, Valencia IC, Covelli C, et al. Eosinophilic, polymorphic, and pruritic eruption associated with radiotherapy. Arch Dermatol 1999; 135:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Donoso C, Tardío JC, Arias D, et al. Eosinophilic, polymorphic and pruritic eruption associated with radiotherapy (EPPER) in two patients with breast tumour. J Eur Acad Dermatol Venereol 2007; 21:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Löbelenz L, Schliep S, Wörl P, Uslu U. Eosinophilic polymorphic and pruritic eruption associated with radiotherapy: case report and overview of disease characteristics. Clin Exp Dermatol 2019; 44:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei KC, Yang KC, Mar GY, et al. STROBE--Radiation Ulcer: An Overlooked Complication of Fluoroscopic Intervention: A Cross-Sectional Study. Medicine (Baltimore) 2015; 94:e2178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hivnor CM, Seykora JT, Junkins-Hopkins J, et al. Subacute radiation dermatitis. Am J Dermatopathol 2004; 26:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeBoit PE. Subacute radiation dermatitis: a histologic imitator of acute cutaneous graft-versus-host disease. J Am Acad Dermatol 1989; 20:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone MS, Robson KJ, LeBoit PE. Subacute radiation dermatitis from fluoroscopy during coronary artery stenting: evidence for cytotoxic lymphocyte mediated apoptosis. J Am Acad Dermatol 1998; 38:333.
          </a>
         </li>
         <li class="breakAll">
          Bridges BA, Adam A, Holt D, et al. High dose radiation effects and tissue injury: Report of the independent advisory group on ionizing radiation. In: Radiation, Chemical, and Environmental Hazards, Elsevier, 2009. Vol RCE-10.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magnusson M, Höglund P, Johansson K, et al. Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: a phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5). Eur J Cancer 2009; 45:2488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobson G, Bhatia S, Smith BJ, et al. Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. Int J Radiat Oncol Biol Phys 2013; 85:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delanian S, Porcher R, Rudant J, Lefaix JL. Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol 2005; 23:8570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gothard L, Stanton A, MacLaren J, et al. Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer. Radiother Oncol 2004; 70:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi AM, Nehal KS, Lee EH. Radiation-induced Breast Telangiectasias Treated with the Pulsed Dye Laser. J Clin Aesthet Dermatol 2014; 7:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos-Juanes J, Coto-Segura P, Galache Osuna C, et al. Treatment of hyperpigmentation component in chronic radiodermatitis with alexandrite epilation laser. Br J Dermatol 2009; 160:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fruchter R, Kurtzman DJ, Mazori DR, et al. Characteristics and treatment of postirradiation morphea: A retrospective multicenter analysis. J Am Acad Dermatol 2017; 76:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mittal A, Mittal V, Panse G, et al. Radiation-induced morphea: Association with autoimmune comorbidities, severity, and response to therapy. J Am Acad Dermatol 2019; 81:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh N, Rheaume D, Barnes P, et al. Postirradiation morphea: an underrecognized complication of treatment for breast cancer. Hum Pathol 2008; 39:1680.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13668 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16310617" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16384753" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20843630" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Acute and chronic radiation injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27250839" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27021652" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Radiodermatitis: A Review of Our Current Understanding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29297172" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Radiation Dermatitis: Recognition, Prevention, and Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514477" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Evidence-based skin care management in radiation therapy: clinical update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12368711" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Wound care after radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22479357" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16168114" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Early and late skin reactions to radiotherapy for breast cancer and their correlation with radiation-induced DNA damage in lymphocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15222781" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A sense of danger from radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21417595" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : After the bomb drops: a new look at radiation-induced multiple organ dysfunction syndrome (MODS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34574012" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acute Radiation Dermatitis Evaluation with Reflectance Confocal Microscopy: A Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19212344" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pravastatin limits radiation-induced vascular dysfunction in the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17379094" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Radiation-induced alterations in cytokine production by skin cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21292447" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Radiation-induced mast cell mediators differentially modulate chemokine release from dermal fibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15850416" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Radiation-induced up-regulation of adhesion molecules in brain microvasculature and their modulation by dexamethasone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16751071" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Curcumin protects against radiation-induced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16751070" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Protective effect of esculentoside A on radiation-induced dermatitis and fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17214513" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Collapse of skin antioxidant status during the subacute period of cutaneous radiation syndrome: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10802350" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19539753" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : TGF-beta and fibrosis in different organs - molecular pathway imprints.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30072193" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Radiation-induced Skin Toxicity in Breast Cancer Patients: A Systematic Review of Randomized Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20697521" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34102298" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17785763" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29895020" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Locoregional Control and Toxicity in Head and Neck Carcinoma Patients following Helical Tomotherapy-Delivered Intensity-Modulated Radiation Therapy Compared with 3D-CRT Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35446337" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Identifying Patients Whose Symptoms Are Underrecognized During Treatment With Breast Radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34710629" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Predictors of Acute Radiation Dermatitis and Esophagitis in African American Patients Receiving Whole-Breast Radiation Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34986553" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical factors affecting the determination of radiotherapy-induced skin toxicity in breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378093" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Burn after breast reconstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10883611" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Radiation therapy after immediate breast reconstruction with implants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22217743" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Ionizing radiation: the good, the bad, and the ugly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21640495" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Predictors of severe acute and late toxicities in patients with localized head-and-neck cancer treated with radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35227594" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : [Prognostic factors of acute radiodermatitis in breast cancer after adjuvant radiotherapy treated with RT3D or IMRT].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18506734" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Toxicity of radiotherapy in patients with collagen vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29316366" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26972857" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Radiotherapy in patients with connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18158195" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Chronic toxicity risk after radiotherapy for patients with systemic sclerosis (systemic scleroderma) or systemic lupus erythematosus: association with connective tissue disorder severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17236971" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Radiotherapy for malignancy in patients with scleroderma: The Mayo Clinic experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15289728" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Severe radiation dermatitis is related to Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37140927" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Association of Staphylococcus aureus Colonization With Severity of Acute Radiation Dermatitis in Patients With Breast or Head and Neck Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16848913" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27878387" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Genetic susceptibility to cutaneous radiation injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29095251" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma: A cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18927311" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26247543" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26247417" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Differences in the Acute Toxic Effects of Breast Radiotherapy by Fractionation Schedule: Comparative Analysis of Physician-Assessed and Patient-Reported Outcomes in a Large Multicenter Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27425588" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Fraction size in radiation therapy for breast conservation in early breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19170238" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29922086" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29198343" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30569265" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Management of severe bio-radiation dermatitis induced by radiotherapy and cetuximab in patients with head and neck cancer: emphasizing the role of calcium alginate dressings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33137440" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18285602" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28503074" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Acute radiation dermatitis in breast cancer patients: challenges and solutions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32398982" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Accelerated Partial Breast Irradiation: A New Standard of Care?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28779963" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31813635" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23942595" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35037118" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : What is the appropriate skin cleaning method for nasopharyngeal cancer radiotherapy patients? A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24484999" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1554631" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11230896" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The impact of skin washing with water and soap during breast irradiation: a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30347008" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Assessing the Validity of Clinician Advice That Patients Avoid Use of Topical Agents Before Daily Radiotherapy Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28733055" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Avoiding antiperspirants during breast radiation therapy: Myth or sound advice?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25194668" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Evaluating the effects of aluminum-containing and non-aluminum containing deodorants on axillary skin toxicity during radiation therapy for breast cancer: a 3-armed randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26619355" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A randomized, double-blind trial on the use of 1% hydrocortisone cream for the prevention of acute radiation dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27913066" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prophylactic treatment with a potent corticosteroid cream ameliorates radiodermatitis, independent of radiation schedule: A randomized double blinded study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20800381" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25585779" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy: results of a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29726361" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28982842" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27957620" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Topical interventions to prevent acute radiation dermatitis in head and neck cancer patients: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22006502" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Topical silver sulfadiazine for the prevention of acute dermatitis during irradiation for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25151541" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Natural oil-based emulsion containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer: a phase 3, double-blind, randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31404344" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Post-lumpectomy Patients with Breast Cancer Receiving Adjuvant Radiation Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31273506" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Novel hyaluronan formulation for preventing acute skin reactions in breast during radiotherapy: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32985288" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Chamomile Gel versus Urea Cream to Prevent Acute Radiation Dermatitis in Head and Neck Cancer Patients: Results from a Preliminary Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31445838" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A single-blind, randomised controlled trial of StrataXRT®- A silicone-based film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24486117" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Prophylactic use of Mepitel Film prevents radiation-induced moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22652101" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Silver clear nylon dressing is effective in preventing radiation-induced dermatitis in patients with lower gastrointestinal cancer: results from a phase III study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31051882" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Phase III Study of Silver Leaf Nylon Dressing vs Standard Care for Reduction of Inframammary Moist Desquamation in Patients Undergoing Adjuvant Whole Breast Radiation Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30802561" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Management of acute radiation dermatitis: A review of the literature and proposal for treatment algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16648511" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15084618" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12464836" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A Phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23245940" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions--results from a randomised blinded trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16149293" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Aloe vera for preventing radiation-induced skin reactions: a systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15542162" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25619686" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Three-Arm Randomized Phase III Trial: Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29742271" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Use of trolamine to prevent and treat acute radiation dermatitis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35059865" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Effect of hyaluronic acid on radiodermatitis in patients with breast cancer: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37140904" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Bacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10921218" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The role of Wobe-Mugos in reducing acute sequele of radiation in head and neck cancers--a clinical phase-III randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15054378" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16751063" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9683362" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23745991" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29192329" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21603988" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Treatment of acute radiodermatitis with an oil-in-water emulsion following radiation therapy for breast cancer: a controlled, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11493094" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Permeability barrier function of skin exposed to ionizing radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34810145" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Symptom Burden Associated With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34810145" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Symptom Burden Associated With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21630130" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17671265" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Severe cutaneous reaction during radiation therapy with concurrent cetuximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487913" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21606209" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21606209" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27825796" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Evaluation of acute skin toxicity in breast radiotherapy with a new quantitative approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26850926" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27249687" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26758559" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26758559" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30878566" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Characterizing the effects of radiation dermatitis on quality of life: A prospective survey-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22301042" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Radiation port dermatophytosis: tinea corporis occurring at the site of irradiated skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3204180" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Radiation port dermatophytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36990615" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26328937" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Hydrosorb®versus control (water based spray) in the management of radio-induced skin toxicity: Results of multicentre controlled randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14007593" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17363185" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Randomized comparison of dry dressings versus hydrogel in management of radiation-induced moist desquamation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18666721" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : RCT on gentian violet versus a hydrogel dressing for radiotherapy-induced moist skin desquamation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10851773" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : The effects of hydrocolloid dressing and gentian violet on radiation-induced moist desquamation wound healing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28247918" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Management of radiodermatitis associated with cetuximab in squamous cell carcinomas of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26817597" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27077276" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy: Update of the Italian Expert Recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21045191" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Radiation recall with anticancer agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15591727" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Frequency of radiation recall dermatitis in adult cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23699661" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Vemurafenib and radiosensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23312391" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Targeted therapy-induced radiation recall.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24743051" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27131079" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28102540" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34277173" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31992119" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Radiation recall dermatitis after treatment of stage IV breast cancer with nivolumab: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23092699" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Radiation burn--from mechanism to management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20082681" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived stem cell administrations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17907931" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20177084" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Medical response to a major radiologic emergency: a primer for medical and public health practitioners.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10411155" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Eosinophilic, polymorphic, and pruritic eruption associated with radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17714133" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Eosinophilic, polymorphic and pruritic eruption associated with radiotherapy (EPPER) in two patients with breast tumour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30406947" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Eosinophilic polymorphic and pruritic eruption associated with radiotherapy: case report and overview of disease characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26632903" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : STROBE--Radiation Ulcer: An Overlooked Complication of Fluoroscopic Intervention: A Cross-Sectional Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15166508" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Subacute radiation dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2915058" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Subacute radiation dermatitis: a histologic imitator of acute cutaneous graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9486710" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Subacute radiation dermatitis from fluoroscopy during coronary artery stenting: evidence for cytotoxic lymphocyte mediated apoptosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9486710" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Subacute radiation dermatitis from fluoroscopy during coronary artery stenting: evidence for cytotoxic lymphocyte mediated apoptosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19540105" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: a phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22846413" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16260695" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15064005" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25584136" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Radiation-induced Breast Telangiectasias Treated with the Pulsed Dye Laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19014400" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Treatment of hyperpigmentation component in chronic radiodermatitis with alexandrite epilation laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27692734" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Characteristics and treatment of postirradiation morphea: A retrospective multicenter analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30797843" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Radiation-induced morphea: Association with autoimmune comorbidities, severity, and response to therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18656234" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Postirradiation morphea: an underrecognized complication of treatment for breast cancer.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
